Background: Clinically lymph node-positive (cN+) prostate cancer (PCa) is an often-fatal disease. Its optimal management remains largely undefined given a lack of prospective, randomized data to inform practice. We sought to describe modern practice patterns in the management of cN+ PCa and assess the effect of adding radiation therapy (RT) to androgen deprivation therapy (ADT) on survival using the National Cancer Data Base.
article positive lymph nodes (pN+) discovered after prostatectomy and/ or lymphadenectomy (10, 11) . However, limited data exist supporting the role for the addition of RT to ADT in patients with cN+ disease identified using modern staging techniques. Using a large national cancer outcomes database, we sought to define current practice patterns for patients with cN+ prostate cancer and compare survival of patients treated with ADT alone vs ADT+RT.
Methods

Data Sources
The National Cancer Data Base (NCDB), a nationwide hospitalbased cancer registry jointly sponsored by the American College of Surgeons (ACoS) and the American Cancer Society, collects data from more than 1400 hospitals accredited by the ACoS Commission on Cancer (CoC). The NCDB captures approximately 70% of all newly diagnosed cancer cases in the United States (12) . It contains standardized data on patient demographic and disease characteristics, insurance status, American Joint Committee on Cancer (AJCC) staging, treatment, and comorbidities. Patient demographic and clinical characteristics captured in the NCDB are comparable with those reported in the Surveillance, Epidemiology, and Ends Results (SEER) database (13) . Additionally, the NCDB collects information on systemic therapy (eg, hormone therapy) and hospital characteristics necessary to understand patterns of care. The NCDB has previously been used to explore trends in cancer treatment, address disparities, and examine outcomes (14) .
Study Population
Male patients aged 18 to 90 years with a new diagnosis of prostate adenocarcinoma (International Classification of Disease for Oncology, 3 rd Edition [ICD-O-3] site code: C61.9), diagnosed between 2004 and 2011, who were diagnosed or received part or all of their first course treatment at a CoC-accredited facility, were identified. The study cohort was then restricted to include patients with regional lymph node metastasis identified before treatment (cN+) and no proven distant metastases (M0 or Mx). Patients treated with radical prostatectomy were also excluded. Patients who had missing information in cancer diagnosis date (n = 13), treatment (n = 21), census region (n = 23), or insurance (n = 109) or had government-sponsored insurance other than Medicaid and Medicare (eg, Bureau of Indian Affairs, Public Health Service) (n = 38) were excluded from the study ( 
Estimated Propensity Score Model
The probability of being treated with ADT+RT was estimated using multivariable logistic regression with all variables listed in Table 2 for the cohort of 983 patients.
Propensity Score Matching
Patients treated with ADT alone were matched to patients treated with ADT+RT who had the closest propensity score (1:1 match) by a greedy 5 to 1 digit matching algorithm. Patients treated with ADT alone who did not have a match to a patient treated with ADT+RT were excluded.
Matched Sample
The final matched sample consisted of 318 patients treated with ADT alone and 318 patients treated with ADT+RT. 
Statistical Analyses
Descriptive analyses were conducted for all patients included in the study population diagnosed between 2004 and 2011. A linear trend test was conducted to examine changes in practice patterns over time. To assess the effect of adding RT to ADT on five-year overall survival (OS), the study population was further restricted to those diagnosed between 2004 and 2006, as full five-year follow-up data was only available for this subcohort. Propensity score matching of patients receiving ADT alone or with RT was performed via the greedy-matching technique to create a subsample adjusted for all available potential confounders (15) . Covariate balance was checked before and after adjustment with chi-square tests. Crude five-year OS rates were estimated for the two treatment modalities using the KaplanMeier approach. Log-rank P values under .05 were considered statistically significant. The assumption of proportionality was tested by Proc Phreg in SAS. If a specific covariate violated the assumption of proportionality, in-strata adjustment was performed in the Cox proportional regression analyses. All other reported P values have a statistical significance level set at P values of less than .05 (two-sided). As the number of involved lymph nodes could potentially affect the choice of treatment, a sensitivity analysis including number of positive lymph nodes as a clinical factor was performed. To further understand whether including cases with missing data would introduce additional confounding, a sensitivity analysis was conducted by excluding patients with missing key clinical characteristics. An additional sensitivity analysis was performed by including patients diagnosed between 2004 and 2011 and censoring those who were still alive at last follow-up. Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC).
Results
Patient Characteristics and Patterns of Practice
A total of 3540 patients were included ( 
Factors Associated With Treatment and Propensity Score Matching
The analysis was then restricted to patients diagnosed between 2004 and 2006 receiving guideline-supported care (ADT alone or ADT+RT). Prior to propensity score matching, the study cohort comprised 388 patients treated with ADT alone and 595 patients treated with ADT+RT. Patients who received combined treatment tended to be younger (P < .001) and were more likely to have private insurance (P < .001), lower comorbidity score (P = .002), higher Gleason grade (P < .001), lower PSA values (P < .001), and clinical T-stage T2 or T3 (P < .001). After propensity score matching, 318 patients remained in each group. The two cohorts were well balanced with no statistically significant differences in the matched factors (Table 2) .
Survival Analyses
Prior to propensity score matching, 47.1% of patients treated with ADT alone and 25.0% of patients treated with ADT+RT died within the five-year follow-up period. The loss-to-follow-up rate was 10.3% and 16.8%, respectively. The crude five-year OS rate was 49.4% for patients treated with ADT alone vs 72.4% for patients treated with RT and ADT (log-rank P <.001) ( Figure 2A ). Combined ADT+RT was associated with a 49.2% decreased risk of five-year all-cause mortality (hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.40 to 0.65, P < .001) compared with ADT alone after adjustment for confounding variables. Among the propensity score-matched subgroups, the crude five-year OS rate among patients treated with ADT alone was still statistically significantly lower than those treated with combined therapy (53.2% vs 71.5%, log-rank P <.001) ( Figure 2B ). After adjusting for patient demographic and clinical characteristics, combined ADT+RT was associated with a statistically significant 50.3% reduction in the risk of five-year all-cause mortality (HR = 0.50, 95% CI = 0.37 to 0.67, P < .001) compared with ADT alone. In addition, patients who were age 75 years and older (P = .05), and those treated at non-NCI-designated cancer centers (P < .05) also had an increased risk of five-year all-cause mortality (Table 3) . To further understand whether the association of treatment and survival varied by age at diagnosis, clinical T-stage, Gleason score, and PSA level, stratified analyses were conducted ( Table 4) . Regardless of age at diagnosis, ADT+RT was associated with statistically significant reduction in the risk of five-year all-cause mortality compared with ADT alone (age <65 years: HR = 0.25, 95% CI = 0.14 to 0.45, P < .001; age ≥65 years: HR = 0.64, 95% CI = 0.44 to 0.95, P = .03). ADT+RT was associated with decreased overall mortality among patients with T1-T2 stage, with a trend among those with T3-T4 disease (T1-T2: As the number of involved lymph nodes could also potentially affect the choice of treatment, we sought to include this factor in our model. Unfortunately these data were only available for 30% of the cohort. We conducted a sensitivity analysis for those patients without missing data for number of involved lymph nodes, and the results were similar to our primary analysis (data not shown). A sensitivity analysis on the subset of patients without missing data for Gleason Score, PSA level, and clinical T-stage was also performed, as was an analysis that included patients diagnosed between 2004 and 2011. Results of both analyses were similar to our original findings (Supplementary Tables  1 and 2 , available online).
Discussion
Using propensity score matching of patient data derived from a large US cancer database, we have identified that the addition of RT to ADT for patients with cN+ prostate cancer decreases five-year all-cause mortality by 50%. Our data also suggest that nearly half of patients with this presentation may not receive optimal therapy with the potential for durable disease control.
Between 2004 and 2011, we found no statistically significant changes in the utilization of ADT or RT in patients with cN+ prostate cancer. This may be because of the paucity of data to inform practice and guidelines that support both ADT alone or along with RT for these patients (5-7). Many physicians use lymph node status as a dividing line between what they consider a curative and noncurative patient, an approach tacitly supported by the current AJCC staging system, which groups node-positive patients along with those known to have distant metastatic disease (2) . Despite this, numerous studies exist, suggesting that patients with isolated lymph node involvement can be long-term survivors and have outcomes approaching those of patients with locally advanced disease (16) (17) (18) (19) . While randomized data exist to support the use of ADT+RT in locally advanced prostate cancer, the ability to extrapolate these results to patients with nodal involvement is limited, as such patients were typically excluded from these trials (4, 9, 20) . The rationale for such therapy remains the same; that is, disease confined to the pelvis can potentially be sterilized by radiotherapy allowing for durable disease control.
There are few previous reports that address the role of a combined modality approach in patients with cN+ prostate cancer. In an unplanned subgroup analysis of cN+ patients included in RTOG 8531, a randomized trial of RT alone vs RT plus ADT for patients with locally advanced prostate cancer, the addition of ADT to RT resulted in a substantial improvement in progression-free and overall survival (nine-year OS rate = 62% vs 38%) (21) . While these data indicated a benefit for combined modality therapy, patient numbers were small (98 receiving ADT+RT and 75 receiving RT alone) and all patients in this trial received RT. Another population-based cancer registry study found that cN+ prostate cancer patients treated with RT had improved overall survival (HR = 0.57, P < .001) and prostate cancer-specific survival (HR = 0.58, P < .001) compared with those not treated with RT (22) . This study, however, cannot comment on the benefit of adding RT to ADT, given that the SEER database lacks information on the use of ADT.
The use of RT alone is an uncommon practice in the modern era (6.2% in our study). Therefore, these data cannot inform the potential differences between ADT alone and ADT+RT, which are the dominant modern management strategies supported by clinical practice guidelines (5-7). RTOG 9608 made an attempt to address this question (ADT +/-RT) in a randomized fashion; however, this trial failed to accrue and was closed.
In another retrospective unmatched single-institution study, Zagars et al. compared outcomes for 255 node-positive prostate cancer patients, 183 of whom received ADT alone and 72 of whom received ADT+RT between 1984 and 1998 (11). Patients treated with combined modality therapy had superior overall survival on univariate and multivariate analysis compared with those treated with ADT alone (five-year OS: 92% vs 83%). All of the patients in this study, however, had subclinical node-positive disease discovered only at the time of staging lymphadenectomy. As patients with bulky radiographically positive lymph nodes may be at higher risk of harboring concomitant but undetectable micrometastatic disease, the relative benefit of adding local treatment with RT was not adequately assessed by this study.
Recent data has also emerged suggesting a role for adjuvant RT for patients with lymph node metastases discovered at the time of radical prostatectomy (10, 23 Table 2 , including age at diagnosis, race/ethnicity, insurance, comorbidity, clinical T stage, Gleason Score, PSA level, and facility type. Even though race/ethnicity and facility type were not shown to be statistically significantly different between the groups, previous reports have suggested possible differences in practice patterns by these factors. Thus, they were included in the final propensity score model (26) (27) (28) (29) (30) . ADT = androgen deprivation therapy; GLS = Gleason Score; NCI = National Cancer Institute; PSA = prostate-specific antigen; RT = radiation therapy. † P values were calculated using Pearson's chi-squared test. ‡ To reduce incomplete propensity score matching, missing data was assigned as a category to be calculated in the propensity score.
at Biomedical Library Gent on August 25, 2015 http://jnci.oxfordjournals.org/ Downloaded from article surgery. Additionally, patients undergoing radical prostatectomy tend to be younger and healthier than prostate cancer patients on the whole, which may increase any potential benefit seen for more aggressive adjuvant therapy in this study. It is important to note, however, that the studies by Briganti et al. and Da Pozzo et al.
were not randomized and so may be subject to substantial selection bias. Regardless, the role of surgery in the multimodal management of cN+ prostate cancer warrants further investigation (1). Our study has several limitations. First, the NCDB is a hospital-based cancer registry that captures only patients who are diagnosed or treated in CoC-accredited facilities. Our results, therefore, may not fully represent the entire cancer population in the United States, though the NCDB does capture approximately 70% of incident cancers each year and previous studies show similar patient characteristics in the NCDB compared with other population-based cohorts (12, 13, 24, 25) . Indeed, our cohort would include a more diverse sample of patients and comorbidities than would be present in a strictly controlled randomized trial or prospective single-institution database. As such, these results may be more generalizable overall and represent "real-world" outcomes for patients with this condition. Second, we are unable to comment on cancer-specific mortality, as such data was not collected. However, overall survival remains the gold standard endpoint relevant to a disease state such as cN+ prostate cancer, which has many events within a few years of diagnosis. Indeed, a recent publication with just over seven years of follow-up demonstrated a statistically significant survival benefit for patients with locally advanced disease when RT was added to ADT (9) . As cN+ prostate cancer is a disease state with an even higher likelihood of leading to lethal prostate cancer, a five-year endpoint is reasonable, though longer follow-up will no doubt improve the conclusions from this study. Third, as this is a retrospective study, we have included all relevant clinical factors associated with disease outcome that are contained in the NCDB to control for possible confounding factors. However, there may still exist some residual unmeasurable confounding factors that we failed to identify and control for, despite the use of propensity score matching and multivariate modeling (such as lymph node size which is not recorded in the NCDB). Though including a larger study population might help to overcome this concern, our study was limited to include only patients having adequate data on prognostic risk factors and five-year follow-up in hopes of providing more accurate and generalizable conclusions. Finally, we are unable to comment on toxicity and quality-of-life differences between the different management strategies.
While prostate cancer patients with lymph node involvement are at high risk for developing distant metastases and death because of prostate cancer, a benefit for local therapy to the pelvis may yet exist. Using data from a large national cancer database, we identify a statistically significant survival benefit for the addition of RT to ADT in cN+ prostate cancer patients. These data also suggest that up to 50% of such patients in the United States are potentially being undertreated. As aggressive local management of cN+ prostate cancer may lead to durable disease control or even cure, these data have important implications for clinical practice guidelines and staging systems. Validation of these data by future prospective and randomized studies is, however, required.
Notes
This study used the National Cancer Data Base (NCDB). The interpretation and reporting of these data are the sole responsibility of the authors. The data used in the study are derived from a deidentified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology employed or the conclusions drawn from these data by the authors.
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